Vaccines, Blood & Biologics
Record of Telephone Conversation - Cervarix, August 11, 2009
RECORD OF TELEPHONE CONVERSATION
Submission Type: Original Application Submission ID: 125259/0 Office: OVRR
Product:
Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant
Applicant:
GlaxoSmithKline Biologicals
Telecon Date/Time: 11-AUG-2009 11:59 AM Initiated by FDA? Yes
Telephone Number:
Communication Categorie(s):
Information Request
Author: HELEN GEMIGNANI
Telecon Summary:
Follow-up Information Request RE: HPV-008 - FDA TC
FDA Participants:
Non-FDA Participants:
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:
From: Matt.Whitman@gsk.com [mailto:Matt.Whitman@gsk.com]
Sent: Tuesday, August 11, 2009 11:59 AM
To: Gemignani, Helen S; Levis, Robin
Cc: Cynthia.A.D'Ambrosio@gsk.com; nicholas.perombelon@gskbio.com
Subject: Fw: Follow-up Information request re: HPV-008 - FDA TC
Hi Helen - here is the requested table for Martha Lee and Nancy Miller. I hope this is the information they needed. Please pass this along and let me know if they need any further information. Thanks Matt.
Please find also source document (this document contains all 14 oncogenic HPV types + HRW & HR and contains complete information)







